Home › Neuroblastoma › Missouri
Neuroblastoma clinical trials in Missouri
10 studies for Neuroblastoma are looking for participants at sites in Missouri.
Cities in Missouri
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- and 1 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Mercy Hospital ( Site 1024), Kansas City
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Cardinal Glennon Children's Medical Center, St Louis
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Cardinal Glennon Children's Medical Center, St Louis
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Cardinal Glennon Children's Medical Center, St Louis
RecruitingPhase 2
Ages 1 to 21 · All sexes · Updated Sep 3, 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- and 1 more
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Washington University School of Medicine, St Louis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Cardinal Glennon Children's Hospital, St Louis
RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Washington University, St Louis
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.